home All News open_in_new Full Article

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Study met primary and secondary endpoints Paridiprubart demonstrated a relative reduction in the risk of death of 25% Treatment provided patients with clinically meaningful improvement in survival and recovery Paridiprubart exhibited consistent safety and tolerability profile TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed […]


today 3 w. ago attach_file Other

attach_file Culture
attach_file Economics
attach_file Other
attach_file Economics
attach_file Economics
attach_file Other


ID: 2145719989
Add Watch Country

arrow_drop_down